{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:10:51Z","timestamp":1767006651843,"version":"3.41.2"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chimeric antigen receptor T (CAR-T) cells are a treatment option for patients with relapse\/refractory (R\/R) non-Hodgkin lymphoma (NHL), acute lymphoid leukemia and multiple myeloma. To date, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) have been successfully treated with CAR-T cells directed against the CD19 antigen. However, when R\/R disease persists after several treatment lines, patients with these diseases are often referred to transplantation centres to receive allogeneic stem cell transplantation (ALLO-SCT). ALLO-SCT and CAR-T cells share mechanism of actions, inducing immune effects of <jats:italic>T<\/jats:italic>-cells (and other cells after transplantation) against lymphoma cells, but they differ in several other characteristics. These differences justify unique positioning of each therapy within treatment algorithms. In this paper, we analyzed the results obtained after ALLO-SCT and CAR-T-cell therapy in patients with aggressive lymphomas (large B-cell lymphoma and MCL) to identify the ideal scenarios in which these 2 immunological therapies should be employed.<\/jats:p>","DOI":"10.3389\/fmed.2022.1072192","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:12:19Z","timestamp":1670303539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Luca","family":"Castagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Tringali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Indovina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Di Noto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia."},{"key":"B3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/annonc\/mdu503","article-title":"90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas","volume":"26","author":"Bouabdallah","year":"2015","journal-title":"Ann Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2017.03.031","article-title":"Allogeneic Stem Cell Transplantation for Relapsed\/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen","volume":"23","author":"Dodero","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbmt.2017.10.013","article-title":"Double-expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation","volume":"24","author":"Kawashima","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2015","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-Intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched sibling donors: a center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"j933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma: results from the US Lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers13174279","article-title":"Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"855730","DOI":"10.3389\/fimmu.2022.855730","article-title":"Best Treatment option for patients with refractory aggressive b-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO\/GETH spanish groups","volume":"13","author":"Bastos-Oreiro","year":"2022","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"30","author":"Kwon","year":"2022","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T-cells in relapsed or refractory diffuse large B cell lymphoma","volume":"22","author":"Bachy","year":"2022","journal-title":"Nat Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive b cell non-hodgkin lymphoma: an expert panel opinion from the american society for transplantation and cellular therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel vs. tisagenlecleucel in relapsed\/refractory large B Cell lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"698607","DOI":"10.3389\/fonc.2021.698607","article-title":"Efficacy and Safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASCTA consensus grading for cytokine release syndorme and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv."},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","author":"Turtle","year":"2016","journal-title":"Sci Transl Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large b-cell lymphoma treated with CD19-chimeric antigen receptor T-Cell THERAPY","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma\u2014advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br J Haematol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the british society for blood and marrow transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"3015","journal-title":"Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B53","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1080\/10428194.2021.1961238","article-title":"Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi","volume":"62","author":"Arcari","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma\u2013final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann Hematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"JCO2102370","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"4","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T-cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? Biol Blood Marrow Transplant","volume":"26","author":"Dreger","year":"2020"},{"key":"B69","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jtct.2021.03.001","article-title":"American society of transplantation and cellular therapy, center of international blood and marrow transplant research, and european society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma","volume":"27","author":"Munshi","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jtct.2022.05.043","article-title":"ASTCT committee on practice guidelines survey on evaluation & management of diffuse large b-cell lymphoma after failure of chimeric antigen receptor t cell therapy (CAR-T) Therapy","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv."},{"key":"B72","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","author":"Zurko","year":"2022","journal-title":"Haematologica"},{"key":"B74","doi-asserted-by":"publisher","first-page":"blood","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis","volume":"19","author":"Di Blasi","year":"2022","journal-title":"Blood."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1072192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:12:21Z","timestamp":1670303541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1072192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":74,"alternative-id":["10.3389\/fmed.2022.1072192"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1072192","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"article-number":"1072192"}}